{"brief_title": "A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia", "brief_summary": "The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.", "condition": ["Schizophrenia"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Lurasidone 20 mg", "Lurasidone 40mg", "Lurasidone 80 mg", "Haloperidol 10mg", "Placebo"], "description": ["Lurasidone 20mg/day tablets", "Lurasidone 40mg/day tablets", "Lurasidone 80mg/day - 2 40mg tablets", "Haloperidol 10mg/day tablets", "Matching Placebo to Lurasdione and Haloperidol"], "arm_group_label": ["Lurasidone 20 mg", "Lurasidone 40 mg", "Lurasidone 80 mg", "Haloperidol 10mg", "Placebo"], "criteria": "Inclusion criteria: - The patient has a primary diagnosis of schizophrenia - The patient has been hospitalized with acute or relapsing schizophrenia within 3 weeks of screening - The patient has had a duration of illness of at least one year. - The patient has a BPRS score of at least 42 at baseline and a score of at least 4 in two or more items of the positive symptom subcluster on the PANSS - The patient is able to remain off antipsychotic medication for a 4 day washout period Exclusion criteria: - The patient has had psychiatric hospitalizations other than current hospitalizations within 1 month prior to screening. - The patient is considered treatment resistant-Substance abuse-Prolactin level of > 200 ng/mL at baseline - Pregnancy", "gender": "All", "minimum_age": "18 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "keyword": "Lurasidone", "mesh_term": ["Schizophrenia", "Lurasidone Hydrochloride", "Haloperidol", "Haloperidol decanoate"], "id": "NCT00044044"}